Page last updated: 2024-11-12

n-((3s)-1-azabicyclo(2.2.2)oct-3-yl)-1h-indazole-3-carboxamide hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-((3S)-1-azabicyclo(2.2.2)oct-3-yl)-1H-indazole-3-carboxamide hydrochloride: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10380472
CHEMBL ID5095032
SCHEMBL ID40976
MeSH IDM0553500

Synonyms (25)

Synonym
909910-22-1
mem 3454
mem3454
rg3487
rg-3487
SCHEMBL40976
O6J463N18M ,
n-((3s)-1-azabicyclo(2.2.2)oct-3-yl)-1h-indazole-3-carboxamide hydrochloride
facinicline hydrochloride
1h-indazole-3-carboxamide, n-(3s)-1-azabicyclo(2.2.2)oct-3-yl-, hydrochloride (1:1)
mem-3454
1h-indazole-3-carboxamide, n-(3s)-1-azabicyclo(2.2.2)oct-3-yl-, monohydrochloride
677305-02-1
unii-o6j463n18m
n-[(3s)-1-azabicyclo[2.2.2]oct-3-yl]-1h-indazole-3-carboxamide hydrochloride
Q27285409
facinicline hcl
677305-02-1(hcl)
MS-24446
facinicline (hydrochloride)
HY-108057A
CS-0081613
n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-3-carboxamide;hydrochloride
AKOS040749293
CHEMBL5095032

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"6-mg/kg doses, producing a bell-shaped dose-response curve."( The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release.
Felix, AR; Huang, M; Kwon, S; Lowe, D; Meltzer, HY; Santarelli, L; Wallace, T, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]